Ram Aiyar Sells 15,152 Shares of Korro Bio (NASDAQ:KRRO) Stock

Korro Bio, Inc. (NASDAQ:KRRO) CEO Ram Aiyar sold 15,152 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $12.98, for a total transaction of $196,672.96. Following the transaction, the chief executive officer directly owned 74,848 shares of the company’s stock, valued at approximately $971,527.04. This trade represents a 16.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Korro Bio Price Performance

Shares of KRRO opened at $11.05 on Thursday. The firm has a 50 day simple moving average of $12.37 and a 200-day simple moving average of $10.52. Korro Bio, Inc. has a 1-year low of $5.20 and a 1-year high of $55.89. The stock has a market cap of $159.27 million, a price-to-earnings ratio of -0.95 and a beta of 3.00.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Korro Bio had a negative return on equity of 117.86% and a negative net margin of 1,834.48%. On average, equities analysts expect that Korro Bio, Inc. will post -5.36 earnings per share for the current fiscal year.

Institutional Trading of Korro Bio

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new stake in shares of Korro Bio during the 3rd quarter valued at $39,000. Wells Fargo & Company MN grew its stake in shares of Korro Bio by 45.5% during the 4th quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after buying an additional 2,352 shares during the period. Guggenheim Capital LLC purchased a new stake in shares of Korro Bio during the 4th quarter valued at $84,000. Jain Global LLC purchased a new stake in shares of Korro Bio during the 4th quarter valued at $85,000. Finally, Deutsche Bank AG grew its stake in shares of Korro Bio by 241.9% during the 4th quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock valued at $102,000 after buying an additional 9,027 shares during the period. 13.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on KRRO. Clear Str raised shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 18th. Lifesci Capital raised shares of Korro Bio to a “strong-buy” rating in a research note on Friday, May 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Korro Bio in a research note on Wednesday, April 8th. Cantor Fitzgerald lifted their target price on shares of Korro Bio from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Friday, March 13th. Finally, HC Wainwright lowered their target price on shares of Korro Bio from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.71.

Key Headlines Impacting Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Negative Sentiment: CEO Ram Aiyar sold 15,152 shares at an average price of $12.98, trimming his stake by 16.84%. Although the company said the sale was to cover tax withholding obligations from vested equity awards, investors often view insider selling as a bearish signal. SEC filing
• Negative Sentiment: Director Jean Francois Formela also sold 2,860 shares at $13.95 under a pre-arranged Rule 10b5-1 trading plan, adding to the recent insider-selling overhang on KRRO. SEC filing
• Neutral Sentiment: Lifesci Capital reiterated a Strong-Buy view on Korro Bio and published earnings estimates that were modestly better than consensus across several future periods. That supports the long-term story, but it does not change the fact that the company is still expected to post significant losses.
• Negative Sentiment: The company’s most recent quarterly report missed EPS expectations, and Korro Bio continues to post large losses, reinforcing concerns about profitability and cash burn.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.